PMID- 32053876
OWN - NLM
STAT- MEDLINE
DCOM- 20210226
LR  - 20211204
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 9
IP  - 2
DP  - 2020 Feb 11
TI  - mTOR Regulation of Metabolism in Hematologic Malignancies.
LID - 10.3390/cells9020404 [doi]
LID - 404
AB  - Neoplastic cells rewire their metabolism, acquiring a selective advantage over 
      normal cells and a protection from therapeutic agents. The mammalian Target of 
      Rapamycin (mTOR) is a serine/threonine kinase involved in a variety of cellular 
      activities, including the control of metabolic processes. mTOR is hyperactivated 
      in a large number of tumor types, and among them, in many hematologic 
      malignancies. In this article, we summarized the evidence from the literature 
      that describes a central role for mTOR in the acquisition of new metabolic 
      phenotypes for different hematologic malignancies, in concert with other 
      metabolic modulators (AMPK, HIF1alpha) and microenvironmental stimuli, and shows how 
      these features can be targeted for therapeutic purposes.
FAU - Mirabilii, Simone
AU  - Mirabilii S
AD  - Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 
      Rome, Italy.
FAU - Ricciardi, Maria Rosaria
AU  - Ricciardi MR
AD  - Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 
      Rome, Italy.
FAU - Tafuri, Agostino
AU  - Tafuri A
AD  - Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 
      Rome, Italy.
AD  - Hematology, "Sant' Andrea" University Hospital, Sapienza University of Rome, 
      00185 Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200211
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
RN  - 0 (HIF1A protein, human)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.3 (AMP-Activated Protein Kinase Kinases)
SB  - IM
MH  - AMP-Activated Protein Kinase Kinases
MH  - Hematologic Neoplasms/genetics/*metabolism/pathology
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/*genetics/metabolism
MH  - Metabolic Networks and Pathways/genetics
MH  - Protein Kinases/*genetics/metabolism
MH  - Signal Transduction/genetics
MH  - TOR Serine-Threonine Kinases/*genetics/metabolism
MH  - Tumor Microenvironment/genetics
PMC - PMC7072383
OTO - NOTNLM
OT  - cell metabolism
OT  - hematologic malignancies
OT  - mTOR
COIS- The authors declare no conflict of interest.
EDAT- 2020/02/15 06:00
MHDA- 2021/02/27 06:00
PMCR- 2020/02/01
CRDT- 2020/02/15 06:00
PHST- 2019/12/06 00:00 [received]
PHST- 2020/02/02 00:00 [revised]
PHST- 2020/02/07 00:00 [accepted]
PHST- 2020/02/15 06:00 [entrez]
PHST- 2020/02/15 06:00 [pubmed]
PHST- 2021/02/27 06:00 [medline]
PHST- 2020/02/01 00:00 [pmc-release]
AID - cells9020404 [pii]
AID - cells-09-00404 [pii]
AID - 10.3390/cells9020404 [doi]
PST - epublish
SO  - Cells. 2020 Feb 11;9(2):404. doi: 10.3390/cells9020404.